Nystagmus Market Research Report–Forecast till 2027

Nystagmus Market Share And Application By Type (Infantile, Latent Nystagmus, Noonan Syndrome, Nystagmus Blockage Syndrome) Diagnosis (Ct Scan, Mr Scan, Chromosome Analysis, Ultrasonography) Treatment (Medication, Surgical) End-User-Forecast Till 2027

ID: MRFR/Pharma/3995-HCR | August 2022 | Region: Global | 110 Pages         

Table of Content


1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Nystagmus Market, by Type

6.1 Introduction

6.2 Infantile

6.2.1 Market Estimates & Forecast, 2020-2027

6.3 Latent Nystagmus

6.3.1 Market Estimates & Forecast, 2020-2027

6.4 Noonan Syndrome

6.4.1 Market Estimates & Forecast, 2020-2027

6.5 Nystagmus Blockage Syndrome

6.5.1 Market Estimates & Forecast, 2020-2027

7. Global Nystagmus Market, by Diagnosis

7.1 Introduction

7.2 CT scan

7.2.1 Market Estimates & Forecast, 2020-2027

7.3 MR scan

7.3.1 Market Estimates & Forecast, 2020-2027

7.4 Others

7.4.1 Market Estimates & Forecast, 2020-2027

8. Global Nystagmus Market, by Treatment

8.1 Introduction

8.2 Medication

8.2.1 Market Estimates & Forecast, 2020-2027

8.3 Surgery

8.3.1 Market Estimates & Forecast, 2020-2027

9. Global Nystagmus Market, by End User

9.1 Introduction

9.2 Hospitals & Clinics

9.2.1 Market Estimates & Forecast, 2020-2027

9.3 Research Centers

9.3.1 Market Estimates & Forecast, 2020-2027

9.4 Others

9.4.1 Market Estimates & Forecast, 2020-2027

10. Global Nystagmus Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 UK

10.3.1.4 Italy

10.3.1.5 Spain

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

12 Company Profiles

12.1 Bristol-Myers Squibb Company

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 NUSAPURE

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 ALLERGAN

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Aerie Pharmaceuticals, Inc.

12.4.1 Company Overview

12.4.2 Product/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Pfizer Inc.

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 Valeant Pharmaceuticals International, Inc

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 Bayer AG

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Others

13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Pharmaceutical Industry

14 Appendix

LIST OF TABLES

Table 1 Nystagmus Industry Synopsis, 2020-2027

Table 2 Global Nystagmus Market Estimates and Forecast, 2020-2027, (USD Million)

Table 3 Global Nystagmus Market by Region, 2020-2027, (USD Million)

Table 4 Global Nystagmus Market by Types, 2020-2027, (USD Million)

Table 5 Global Nystagmus Market by Diagnosis, 2020-2027, (USD Million)

Table 6 Global Nystagmus Market by Treatment, 2020-2027, (USD Million)

Table 7 Global Nystagmus Market by End Users, 2020-2027, (USD Million)

Table 8 North America Nystagmus Market by Types, 2020-2027, (USD Million)

Table 9 North America Nystagmus Market by Diagnosis, 2020-2027, (USD Million)

Table 10 North America Nystagmus Market by Treatment, 2020-2027, (USD Million)

Table 11 North America Nystagmus Market by End Users, 2020-2027, (USD Million)

Table 12 US Nystagmus Market by Types, 2020-2027, (USD Million)

Table 13 US Nystagmus Market by Diagnosis, 2020-2027, (USD Million)

Table 14 US Nystagmus Market by Treatment, 2020-2027, (USD Million)

Table 15 US Nystagmus Market by End Users, 2020-2027, (USD Million)

Table 16 Canada Nystagmus Market by Types, 2020-2027, (USD Million)

Table 17 Canada Nystagmus Market by Diagnosis, 2020-2027, (USD Million)

Table 18 Canada Nystagmus Market by Treatment, 2020-2027, (USD Million)

Table 19 Canada Nystagmus Market by End Users, 2020-2027, (USD Million)

Table 20 South America Nystagmus Market by Types, 2020-2027, (USD Million)

Table 21 South America Nystagmus Market by Diagnosis, 2020-2027, (USD Million)

Table 22 South America Nystagmus Market by Treatment, 2020-2027, (USD Million)

Table 23 South America Nystagmus Market by End Users, 2020-2027, (USD Million)

Table 24 Europe Nystagmus Market by Types, 2020-2027, (USD Million)

Table 25 Europe Nystagmus Market by Diagnosis, 2020-2027, (USD Million)

Table 26 Europe Nystagmus Market by Treatment, 2020-2027, (USD Million)

Table 27 Europe Nystagmus Market by End Users, 2020-2027, (USD Million)

Table 28 Western Europe Nystagmus Market by Types, 2020-2027, (USD Million)

Table 29 Western Europe Nystagmus Market by Diagnosis, 2020-2027, (USD Million)

Table 30 Western Europe Nystagmus Market by Treatment, 2020-2027, (USD Million)

Table 31 Western Europe Nystagmus Market by End Users, 2020-2027, (USD Million)

Table 32 Eastern Europe Nystagmus Market by Types, 2020-2027, (USD Million)

Table 33 Eastern Europe Nystagmus Market by Diagnosis, 2020-2027, (USD Million)

Table 34 Eastern Europe Nystagmus Market by Treatment, 2020-2027, (USD Million)

Table 35 Eastern Europe Nystagmus Market by End Users, 2020-2027, (USD Million)

Table 36 Asia Pacific Nystagmus Market by Types, 2020-2027, (USD Million)

Table 37 Asia Pacific Nystagmus Market by Diagnosis, 2020-2027, (USD Million)

Table 38 Asia Pacific Nystagmus Market by Treatment, 2020-2027, (USD Million)

Table 39 Asia Pacific Nystagmus Market by End Users, 2020-2027, (USD Million)

Table 40 Middle East & Africa Nystagmus Market by Types, 2020-2027, (USD Million)

Table 41 Middle East & Africa Nystagmus Market by Diagnosis, 2020-2027, (USD Million)

Table 42 Middle East & Africa Nystagmus Market by Treatment, 2020-2027, (USD Million)

Table 43 Middle East & Africa Nystagmus Market by End Users, 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Nystagmus Market

Figure 3 Segmentation Market Dynamics for Nystagmus Market

Figure 4 Global Nystagmus Market Share, by Diagnosis 2020

Figure 5 Global Nystagmus Market Share, by Treatment 2020

Figure 6 Global Nystagmus Market Share, by End Users, 2020

Figure 7 Global Nystagmus Market Share, by Region, 2020

Figure 8 North America Nystagmus Market Share, by Country, 2020

Figure 9 Europe Nystagmus Market Share, by Country, 2020

Figure 10 Asia Pacific Nystagmus Market Share, by Country, 2020

Figure 11 Middle East & Africa Nystagmus Market Share, by Country, 2020

Figure 12 Global Nystagmus Market: Company Share Analysis, 2020 (%)

Figure 13 Bristol-Myers Squibb Company: Key Financials

Figure 14 Bristol-Myers Squibb Company: Segmental Revenue

Figure 16 Bristol-Myers Squibb Company: Geographical Revenue

Figure 17 NUSAPURE: Key Financials

Figure 18 NUSAPURE: Segmental Revenue

Figure 19 NUSAPURE: Geographical Revenue

Figure 20 ALLERGAN: Key Financials

Figure 21 ALLERGAN: Segmental Revenue

Figure 22 ALLERGAN: Geographical Revenue

Figure 23 Aerie Pharmaceuticals, Inc: Key Financials

Figure 24 Aerie Pharmaceuticals, Inc: Segmental Revenue

Figure 25 Aerie Pharmaceuticals, Inc: Geographical Revenue

Figure 26 Pfizer Inc: Key Financials

Figure 27 Pfizer Inc: Segmental Revenue

Figure 28 Pfizer Inc: Geographical Revenue

Figure 29 Valeant Pharmaceuticals International, Inc.: Key Financials

Figure 30 Valeant Pharmaceuticals International, Inc.: Segmental Revenue

Figure 31 Valeant Pharmaceuticals International, Inc.: Geographical Revenue

Figure 32 Bayer AG: Key Financials

Figure 33 Bayer AG: Segmental Revenue

Figure 34 Bayer AG: Geographical Revenue

Nystagmus Market

Nystagmus Market is projected to be worth USD 3.8 Billion by 2028, registering a CAGR of 7.2% during the forecast period (2021 - 2028).

Segmentation

By Type Infantile Latent Nystagmus Noonan Syndrome Nystagmus Blockage Syndrome
By Diagnosis Ct Scan Mr Scan Chromosome Analysis Ultrasonography
By Treatment Medication Surgical

Key Players

  • Bristol-Myers Squibb Company
  • NUSAPURE
  • ALLERGAN
  • Aerie Pharmaceuticals Inc.
  • Pfizer Inc.
  • Valeant Pharmaceuticals International.
  • Bayer AG
  • Genentech Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.
  • Shire
  • Santen Pharmaceutical Co. Ltd.

Drivers

  • Increasing prevalence of the genetic and eye related disorders
  • Increasing mental retardation and neurological abnormalities
Speak to Analyst Request a Free Sample

Nystagmus Market Overview


The global nystagmus market is expected to grow at a CAGR of approximately 6.2% during the forecast period, 2017-2023.  Nystagmus is a vision-related medical disease characterized by uncontrolled and repeated eye movements. These motions frequently result in blurred vision, which may wreak havoc on the body's balance and coordination. The prognosis of nystagmus is worsened by fatigue and stress. The specific source of the disease, however, is yet unknown. Congenital neurological problems or neurological abnormalities developing in childhood are the most common causes of nystagmus.


Nystagmus can also be caused by a lack of normal eye movement in childhood, refractive errors such as near-sightedness (myopia) or astigmatism, inflammation of the inner ear, medicines such as anti-epilepsy treatments, and central nervous system illnesses. The rising frequency of genetic and eye-related illnesses is driving the expansion of the nystagmus industry. Furthermore, the market will grow as mental retardation and neurological disorders become more prevalent.


Global Nystagmus Market, by region 2016(%)


 global nystagmus


Segmentation:


The nystagmus market is segmented on the basis of type, diagnosis, treatment, and end-users.


Based on the type, the market is segmented into infantile, latent nystagmus, noonan syndrome, and nystagmus blockage syndrome.


On the basis of the diagnosis, the market is segmented into CT scan, MR scan, chromosome analysis, ultrasonography, and others.


On the basis of the treatment, the market is segmented into medications, surgical, and others.


On the basis of the end-user, the market is segmented into hospitals & clinics, research centers, specialty eye clinics, and others.


Regional Analysis:


The global nystagmus market consists of countries namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.


The Americas dominate the global nystagmus market owing to well-developed technology, increasing number of patients with eye-related problems, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies in the region have fuelled the growth of the market in this region.  


Europe holds the second position in the global nystagmus market owing to the government support for research & development and availability of funds for research. Moreover, this is expected to continue to drive the European market over the forecasted period. For instance, countries like Germany and France are increasing their investments in the healthcare domain.     


Asia Pacific is the fastest growing nystagmus market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods for eye diseases in countries like India and South Korea is likely to emerge as the fastest growing market across the globe. Furthermore, growing demand for quality devices in the healthcare sector is projected to lead the use of advanced equipment, which, in turn, will increase the market growth of nystagmus in the region.  


On the other hand, in the Middle East and Africa, eye problems have become a huge issue due to limited screening, ignorance of diseases, and poor access to treatment.


Key Players:


Some of key the players in the global nystagmus market are Bristol-Myers Squibb Company, NUSAPURE, ALLERGAN, Aerie Pharmaceuticals, Inc., Pfizer Inc., Valeant Pharmaceuticals International, Inc., Bayer AG, Genentech, Inc., Novartis AG , Regeneron Pharmaceuticals, Inc., Shire, and Santen Pharmaceutical Co., Ltd., and others.

Recent Development


Regeneron Pharmaceuticals, Inc. is a biotechnology business that specializes in drug research, development, manufacturing, and commercialization. EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP are among the company's product lines. The company's own VelociSuite technologies, such as VelocImmune, which employs genetically humanized mice to manufacture optimized totally human and bispecific antibodies, help to speed up the traditional drug development process.


Bristol-Myers Squibb is a biopharmaceutical corporation. Biopharmaceutical products are discovered, developed, licensed, manufactured, marketed, distributed, and sold by the company. Oncology, immunology, cardiovascular disease, and fibrosis are among the therapeutic classes for which the company produces pharmaceuticals. Chemically manufactured or tiny molecule medications, as well as biologics created through biological processes, are among the company's pharmaceutical goods. Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude, and Breyanzi are some of the company's products. Wholesalers, distributors, pharmacies, merchants, hospitals, clinics, and government organizations are all customers of its goods.


Intended Audience:



  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Research Methodology:


  nystagmus


Sources: Annual reports, Press release, White paper, and Company presentation



Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2017-2023:6.1%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, diagnosis, treatment, and end-users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Bristol-Myers Squibb Company, NUSAPURE, ALLERGAN, Aerie Pharmaceuticals, Inc., Pfizer Inc., Valeant Pharmaceuticals International, Inc., Bayer AG, Genentech, Inc., Novartis AG , Regeneron Pharmaceuticals, Inc., Shire, and Santen Pharmaceutical Co., Ltd., and others
  Key Market Opportunities

  • Increasing number of patients with eye-related problems
  • High healthcare spending
  • Increasing government support for research & development
  •   Key Market Drivers

  • Increasing prevalence of the genetic and eye related disorders
  • Increasing mental retardation and neurological abnormalities


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Nystagmus market is expected to exhibit a CAGR of 6.2% from 2017 to 2023.

    Nystagmus market is driven by the high prevalence of genetic and eye disorders.

    Lack of effective reimbursement schemes and offering of expensive treatment can hamper the global nystagmus market growth.

    The Americas can be dominant in the global nystagmus market till 2023.

    Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Bayer AG, NUSAPURE, ALLERGAN, Novartis AG, Genentech, Inc., Aerie Pharmaceuticals, Inc., Pfizer Inc., Shire, Bristol-Myers Squibb Company, and Valeant Pharmaceuticals International, Inc. are key players of the global nystagmus market.